ArticleBMC endocrine disorders2025
Associations of trimethylamine N-oxide (TMAO) and its precursors with childhood obesity: a case-control study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiota-Derived Metabolites in Developmental Programming: Bridging Early-Life Gut Microbiota to Childhood Metabolic Disorders.Current medical science · 2026Review
- Gut microbiota-immune crosstalk in childhood and adolescent obesity: mechanistic insights and therapeutic potential focused on short-chain fatty acids and emerging metabolites.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging studies suggests a potential link between serum trimethylamine N-oxide (TMAO) and obesity in adults. However, data on this association in children remain scarce. The present study aimed to investigate the association of TMAO and its precursors with childhood obesity and to evaluate whether such associations would be modified by basic clinical characteristics.
methodsWe conducted a case-control study involving 50 children with obesity and 50 children with normal weight aged 2–6 years. Serum TMAO and its precursors were quantified by ultra high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Multivariate logistic regression models and Pearson correlation analyses were performed after controlling several confounding factors.
resultsSerum choline was inversely associated with childhood obesity (OR (95% CI) for highest vs. lowest quartile: 0.16 (0.04, 0.61), p = 0.007), whereas serum creatinine and carnitine showed positive correlations (ORs: 30.03 and 5.31, p < 0.001 and p = 0.011 respectively). We also found that choline was negatively correlated with BMI (p = 0.038), whereas creatinine and carnitine were positively correlated with BMI (p < 0.001 and p = 0.002, respectively). in addition, subgroup analyses based on sex, age groups, and maternal gestational diabetes mellitus status showed generally consistent results, with no significant interactions. No significant associations of betaine, TMA and TMAO with childhood obesity were observed (all p > 0.05).
conclusionHigher serum choline levels were associated with lower odds of childhood obesity, while elevated creatinine and carnitine levels were associated with higher odds. These findings provide hints regarding the potential significance of these metabolites, which can be influenced by gut microbiota activity, diet, and host metabolism, in early-life obesity. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.